Biocracked
Approach: conceptual metaphor. Palette: bold color field.

Subject: a heavy steel hand-brake lever from a bicycle or machine, shown in tight close-up, half-released with its cable going slack. A taut, braided rope of dense red muscle-like fibers runs through the frame, pulling free of the brake. The surface is lightly scuffed and brushed, with a thin electric green (#00e676) cable sleeve as the one small accent.

Camera: low three-quarter angle, 85mm lens, shallow depth of field, the lever sharp in the foreground and the rope softening behind it.

Lighting: crisp, directional studio light from the upper left, with hard-edged but clean shadows and warm highlights on the metal.

Backdrop: a seamless, saturated mustard-yellow field, evenly lit and uncluttered, with no blue cast anywhere.

Mood: tense but hopeful, a mechanism being released, with a hint of caution in the sharp shadows.
Longevity

Myostatin Blocker Cuts Semaglutide Muscle Loss, With a Catch

Dr. Synapse · · 4 min read

Semaglutide can melt fat. It can also take muscle with it. A large new phase 2 trial in The Lancet asked whether blocking the body's "brakes" on muscle growth could prevent that loss. The answer is a qualified yes, and one version of the treatment came with a safety signal that deserves attention.

Here is what the COURAGE trial found, what it didn't, and what GLP-1 users can actually do today.

The Problem: Rapid Weight Loss Isn't Only Fat

The weight loss from GLP-1 receptor agonists comes with pronounced muscle loss. In COURAGE, people on semaglutide plus placebo lost 6.6% of their lean mass at 26 weeks (95% CI −7.4 to −5.7). In the 52-week part of the trial, the placebo group's lean mass fell 7.3%.

Lean mass is not identical to skeletal muscle, but it is the trial's primary measure and a standard proxy.

The Idea: Block Myostatin (GDF8) and Activin A

GDF8, better known as myostatin, and activin A act through ActRIIA/B receptors as negative regulators of muscle mass. Regeneron tested two antibodies:

  • Trevogrumab, which blocks GDF8 and was given weekly by subcutaneous injection.
  • Garetosmab, which blocks activin A and was given intravenously every 4 weeks.

The Trial: 975 People, Two Parts

The study was a double-blind, placebo-controlled phase 2 trial at 60 US sites. It enrolled 975 adults with obesity (BMI ≥30), with a mean age of 49 and a mean BMI of 36.7. Sixty-four percent were female. Everyone took semaglutide, titrated to 2.4 mg weekly.

  • Part A (26 weeks, n=605): placebo, trevogrumab 200 mg, trevogrumab 400 mg, or trevogrumab 400 mg plus garetosmab 10 mg/kg.
  • Part B (52 weeks, n=376): placebo, trevogrumab 25 mg, or trevogrumab 75 mg.

The Headline Numbers: Lean Mass

The figures below are estimated treatment differences versus semaglutide plus placebo.

Part A (26 weeks):

  • Trevogrumab 200 mg: +3.1% (95% CI 1.9 to 4.3)
  • Trevogrumab 400 mg: +2.7% (1.5 to 4.0)
  • Trevogrumab 400 mg plus garetosmab: +4.5% (3.1 to 5.9)

Part B (52 weeks):

  • Trevogrumab 25 mg: +1.5% (−0.3 to 3.3), not statistically significant
  • Trevogrumab 75 mg: +3.1% (1.3 to 4.9)

The treatments reduced lean-mass loss but did not eliminate it. The abstract does not report absolute lean-mass change for the treatment arms, so any "net loss" figure for them would be our own arithmetic.

Fat Loss and Weight: A Surprise

Muscle-sparing drugs are sometimes assumed to trade away fat loss. Here the opposite happened in some arms.

  • The placebo group lost 15.6% of fat mass in part A.
  • Trevogrumab 400 mg alone produced significantly greater fat loss (ETD −3.4%).
  • The trevogrumab plus garetosmab combination produced a much larger additional fat loss (ETD −11.7%).
  • Bodyweight fell 10.6% on semaglutide plus placebo. Only the combination significantly improved on that, by an extra 2.7 percentage points.
  • No other part A group and no part B group differed significantly in fat mass or bodyweight.

The Catch: The Combination's Safety Profile

Trevogrumab alone, at 25, 75, 200 or 400 mg, was generally well tolerated, with a safety profile similar to semaglutide plus placebo. Gastrointestinal events were the most common and occurred at similar rates across groups. Most adverse events were mild to moderate.

The trevogrumab 400 mg plus garetosmab group was different:

  • Serious adverse events: 14 of 149 (9%)
  • Treatment discontinuations: 48 of 149 (32%)
  • Muscle spasms: 61 of 149 (41%), versus 8% (23 of 299) in the trevogrumab-alone groups and 5% (7 of 151) on placebo
  • Deaths: two during the study, both in this group. The investigators did not identify a causal association.

The authors conclude that the combination "did not have favourable safety and tolerability." They frame trevogrumab alone as the proof of concept.

Caveats

  • Sponsorship: The trial was funded by Regeneron, and many authors are Regeneron employees and shareholders.
  • Phase 2: The primary endpoints were body composition and weight, not function. The authors say further study is needed to see whether preserved lean mass translates into better physical function and metabolic health.
  • Not approved: Neither antibody is approved for this use. You cannot get them as a supplement or prescription.
  • Withdrawal phase: Part A included a 26-week period after semaglutide was stopped, but the abstract reports no results from it.

What This Means for GLP-1 Users Now

The following is general guidance, not a finding from this study, which tested neither exercise nor diet.

  • Do not chase this drug class. There is no dose, timing or "who it's for" because nothing is available outside trials.
  • Prioritize protein and resistance training. These are the widely recommended, accessible ways to defend muscle during weight loss. Discuss the protein target and exercise plan with your clinician or a dietitian, especially if you have kidney disease.
  • Track more than the scale. Strength, function and, where possible, body composition tell you more than weight alone.

Timeline

The abstract gives no approval timeline. COURAGE is active but not recruiting. Because the combination's safety profile was concerning and function was not assessed, further trials would be needed before any regulator could consider these drugs. Treat this as a promising early signal, not an imminent option.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: bold color field.

A single ripe, glossy red tomato-colored apple sits at the center of a saturated mustard-yellow seamless backdrop, with a neat row of five identical white capsules lined up beside it on the same surface. The apple is the clear winner of the frame. One capsule has rolled slightly away, cracked open and spilling a tiny pile of pale powder. Shot at a low three-quarter angle with a shallow depth of field, so the back capsules blur softly. Lighting is a large, soft key light from the upper left, giving crisp but gentle shadows with warm yellow bounce. A thin sprig of electric green (#00e676) leaves rises from the apple stem as the only green accent. Mood: confident, playful and skeptical, a clean verdict that real food outweighs pills. No text or labels.
longevity

Zombie Cell Supplements? 27 Human Trials Say Diet Beats Pills

BY NOVA CHEN ·

Supplement labels love to promise they'll "clear zombie cells," but a new systematic review of 27 human trials and 3,811 participants suggests the evidence is thin. Calorie restriction produced the most consistent drop in senescence-linked inflammatory signals. Omega-3 was the most promising supplement, though the evidence was limited and mixed. Telomere length and the classic p16/p21 markers mostly failed to move. Here's what that means for what you eat and what you buy.

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Calmed 'Old' Platelets in Aged Mice—Here's the Catch

BY NOVA CHEN ·

A new Aging Cell study reports that CoQ10 improved the function of aged megakaryocytes, the bone marrow cells that make platelets, in mice. Treated animals showed reduced platelet aggregation and activation, though platelet counts didn't change. The effect appeared to run partly through COPS3 and autophagy, the cell's recycling system. But this was mouse and cell-line research with no human data and no proof of clot prevention. Here is what it means, what it doesn't, and why people on blood thinners should talk to a doctor first.

Approach 2, lab in action, with palette D, bold color field.

Overhead-angled close shot of a gloved hand in a pale purple nitrile glove holding an open agar petri dish above a saturated mustard-yellow lab bench. Inside the dish, dozens of tiny translucent C. elegans worms trace sinuous curved tracks across a faintly glowing bacterial lawn. A small cluster of the worms shows a subtle electric green fluorescence along their bodies, suggesting neurons. Beside the dish, a microcentrifuge tube holds a pale golden-yellow DHM solution, with a pipette tip hovering nearby. Lighting is bright, crisp, directional studio-style lab light with soft short shadows. The shallow depth of field blurs the background to a smooth yellow. The mood is curious, precise and optimistic, with a slightly playful contrast between the vivid backdrop and the delicate, nearly invisible animals.
longevity

Hangover Supplement DHM Stretched Worm Lifespan by Up to 15%

BY NOVA CHEN ·

The same compound sold in hangover capsules just stretched worm lifespan by up to 15%. In a new C. elegans study, dihydromyricetin (DHM) also protected touch-receptor neurons, kept the worms moving longer, and lowered intestinal fat. The lifespan effect did not depend on the classic longevity gene daf-16, and standard antioxidant reporters were not induced, which hints at a more unusual mechanism. But this is worms only, the micromolar doses do not translate to capsule doses, and there is no human longevity data.

**Approach: Macro science. Palette: Bold color field (saturated magenta).**

Extreme macro photograph of fisetin-like yellow needle crystals growing from a single point, with two larger, more geometric, translucent amber-gold crystals standing slightly apart as the "upgraded" versions. The crystals show real facets, internal fractures and sharp refractive edges. They rest on a glossy, saturated magenta surface that fills the background in a smooth gradient and reflects a faint mirror image of the crystals. Shot from a low three-quarter angle with a shallow depth of field, so the foreground crystal tips are razor sharp and the rest melts into soft magenta bokeh. Lighting is a crisp, warm-white key from the upper left, with strong specular highlights and a thin rim of electric green (#00e676) light catching one crystal edge. Mood: precise, curious, and slightly skeptical, like a lab specimen under scrutiny.
longevity

Fisetin Not Strong Enough? Scientists Built Two Upgraded Versions

BY DR. SYNAPSE ·

Scientists behind a new Aging Cell paper say fisetin, a senolytic already in clinical trials, has suboptimal efficacy and poor bioavailability, so they engineered two upgraded versions. The compounds, SR29384 and SR31133, reduced tissue senescence and improved healthspan-related measures in mouse models of aging. But there are no human data, the molecules aren't for sale, and the authors disclose a startup and a provisional patent tied to them. Here's what that means if you take fisetin today, and who should be cautious.

This page is available in